These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15304503)

  • 21. Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs.
    Sato T; Nyborg AC; Iwata N; Diehl TS; Saido TC; Golde TE; Wolfe MS
    Biochemistry; 2006 Jul; 45(28):8649-56. PubMed ID: 16834339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
    Leuchtenberger S; Kummer MP; Kukar T; Czirr E; Teusch N; Sagi SA; Berdeaux R; Pietrzik CU; Ladd TB; Golde TE; Koo EH; Weggen S
    J Neurochem; 2006 Jan; 96(2):355-65. PubMed ID: 16300630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.
    Beher D; Wrigley JD; Owens AP; Shearman MS
    J Neurochem; 2002 Aug; 82(3):563-75. PubMed ID: 12153480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
    Czirr E; Weggen S
    Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Purification and characterization of the human gamma-secretase complex.
    Fraering PC; Ye W; Strub JM; Dolios G; LaVoie MJ; Ostaszewski BL; van Dorsselaer A; Wang R; Selkoe DJ; Wolfe MS
    Biochemistry; 2004 Aug; 43(30):9774-89. PubMed ID: 15274632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.
    Moore CL; Leatherwood DD; Diehl TS; Selkoe DJ; Wolfe MS
    J Med Chem; 2000 Sep; 43(18):3434-42. PubMed ID: 10978191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in gamma-secretase modulation.
    Pissarnitski D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors.
    Tian G; Ghanekar SV; Aharony D; Shenvi AB; Jacobs RT; Liu X; Greenberg BD
    J Biol Chem; 2003 Aug; 278(31):28968-75. PubMed ID: 12719412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
    Czirr E; Cottrell BA; Leuchtenberger S; Kukar T; Ladd TB; Esselmann H; Paul S; Schubenel R; Torpey JW; Pietrzik CU; Golde TE; Wiltfang J; Baumann K; Koo EH; Weggen S
    J Biol Chem; 2008 Jun; 283(25):17049-54. PubMed ID: 18426795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.
    Kukar T; Golde TE
    Curr Top Med Chem; 2008; 8(1):47-53. PubMed ID: 18220932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
    Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
    Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.
    Zhang L; Song L; Terracina G; Liu Y; Pramanik B; Parker E
    Biochemistry; 2001 Apr; 40(16):5049-55. PubMed ID: 11305921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
    Beher D; Graham SL
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of gamma-secretase inhibitors and modulators.
    Imbimbo BP
    Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease.
    Lammich S; Kojro E; Postina R; Gilbert S; Pfeiffer R; Jasionowski M; Haass C; Fahrenholz F
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3922-7. PubMed ID: 10097139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
    Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
    Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuing strategies for inhibiting Alzheimer's gamma-secretase.
    Wolfe MS; Esler WP; Das C
    J Mol Neurosci; 2002; 19(1-2):83-7. PubMed ID: 12212799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APPepsilon, the epsilon-secretase-derived N-terminal product of the beta-amyloid precursor protein, behaves as a type I protein and undergoes alpha-, beta-, and gamma-secretase cleavages.
    Lefranc-Jullien S; Sunyach C; Checler F
    J Neurochem; 2006 May; 97(3):807-17. PubMed ID: 16524370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.